Silver Book Fact

In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.

Rascol, Olivier, David J. Brooks, Amos D. Korczyn, Peter P. DeDeyn, Carl E. Clarke, and Anthony E. Lang, for The 056 Study Group. A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa. N Engl J Med. 2000; 342(20): 1484-91. http://content.nejm.org/cgi/content/abstract/342/20/1484

Reference

Title
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson’s Disease Who Were Treated with Ropinirole or Levodopa
Publication
N Engl J Med
Publication Date
2000
Authors
Rascol, Olivier, David J. Brooks, Amos D. Korczyn, Peter P. DeDeyn, Carl E. Clarke, and Anthony E. Lang, for The 056 Study Group
Volume & Issue
Volume 342, Issue 20
Pages
1484-91
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the Medicare costs for people with the disease by $20 billion…  
  • Medicare Costs, Slowed Progression  
  • Research shows that use of donepezil leads to a 4-fold increase in drug costs; however, it significantly lowers overall medical costs, reducing medical treatment and prescription drug costs by $3,891…  
  • An Alzheimer’s treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce out-of-pocket costs to people with the disease by $8 billion in 2020–from the…  
  • Slowing the progression of Parkinson’s disease by just 10% would save $327 million (in direct and indirect costs) to the U.S. annually.